Trastuzumab as a Preoperative Monotherapy Does Not Inhibit HER2 Downstream Signaling in HER2-Positive Breast Cancer

A recent study showed that trastuzumab inhibits the MAPK and PI3K pathways for cell lines overexpressing HER2, but not on HER2-overexpressing tumors that have received preoperative treatment as a monotherapy. According to the results, the inhibition of oncogenic signaling pathways may not be the main mode of action employed, when trastuzumab is administered alone in chemotherapy-naïve patients. Alternative molecular mechanisms, such as the modulation of immune pathways, should be considered.

 Oncology Letters

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.